Expanding Treatment of Tobacco Dependence

Overview

Journal Curr Psychiatry Rep

Publisher Current Science

Specialty Psychiatry

Date 2005 Oct 12

PMID 16216152

Citations 4

Authors

Debra S Harris

Robert M Anthenelli

Affiliations

Soon will be listed here.

Abstract

Nicotine dependence is the leading preventable cause of adult morbidity and mortality in the world. New research on the treatment of this disorder ranges from studies evaluating access to treatment to studies elucidating the molecular mechanisms of nicotine addiction. As our understanding of the neurobiology of tobacco addiction grows, the number of potential therapeutic targets by which we can intervene in this pernicious disorder also increases. This paper presents an overview of recent research trends in the treatment of tobacco dependence. We review several novel mechanisms of action that may serve as therapeutic targets for the pharmacologic treatment of tobacco dependence, including drugs that affect monamine oxidase, selective nicotinic receptors, glutamate and gamma-aminobutyric acid receptors, and the endocannabinoid system. For each of these therapeutic targets, we discuss medications in development that affect these pathophysiologic mechanisms.

Citing Articles

Functional Upregulation of α4* Nicotinic Acetylcholine Receptors in VTA GABAergic Neurons Increases Sensitivity to Nicotine Reward.

Ngolab J, Liu L, Zhao-Shea R, Gao G, Gardner P, Tapper A J Neurosci. 2015; 35(22):8570-8.

PMID: 26041923 PMC: 4588598. DOI: 10.1523/JNEUROSCI.4453-14.2015.

Increased CRF signalling in a ventral tegmental area-interpeduncular nucleus-medial habenula circuit induces anxiety during nicotine withdrawal.

Zhao-Shea R, DeGroot S, Liu L, Vallaster M, Pang X, Su Q Nat Commun. 2015; 6:6770.

PMID: 25898242 PMC: 4405813. DOI: 10.1038/ncomms7770.

Smoking cessation: an economic analysis and review of varenicline.

Faulkner M Clinicoecon Outcomes Res. 2011; 1:25-34.

PMID: 21935304 PMC: 3169991. DOI: 10.2147/ceor.s4223.

Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders.

Fernandez-Ruiz J, Hernandez M, Ramos J CNS Neurosci Ther. 2010; 16(3):e72-91.

PMID: 20406253 PMC: 6493786. DOI: 10.1111/j.1755-5949.2010.00144.x.

References

George T, Vessicchio J, Termine A, Jatlow P, Kosten T, OMalley S . A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry. 2003; 53(2):136-43. DOI: 10.1016/s0006-3223(02)01454-3. View

Fowler J, Logan J, Wang G, Volkow N, Telang F, Zhu W . Low monoamine oxidase B in peripheral organs in smokers. Proc Natl Acad Sci U S A. 2003; 100(20):11600-5. PMC: 208804. DOI: 10.1073/pnas.1833106100. View

Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M . The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003; 112(3):423-31. PMC: 166293. DOI: 10.1172/JCI17725. View

Barrett J, Szego P, Rohatagi S, Morales R, De Witt K, Rajewski G . Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males. Pharm Res. 1996; 13(10):1535-40. DOI: 10.1023/a:1016035730754. View

Cohen C, Perrault G, Griebel G, Soubrie P . Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology. 2004; 30(1):145-55. DOI: 10.1038/sj.npp.1300541. View

Biberman R, Neumann R, Katzir I, Gerber Y . A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction. 2003; 98(10):1403-7. DOI: 10.1046/j.1360-0443.2003.00524.x. View

Gourlay S, Stead L, Benowitz N . Clonidine for smoking cessation. Cochrane Database Syst Rev. 2004; (3):CD000058. PMC: 7038651. DOI: 10.1002/14651858.CD000058.pub2. View

Pontieri F, Tanda G, Orzi F, Di Chiara G . Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature. 1996; 382(6588):255-7. DOI: 10.1038/382255a0. View

Rose J, Brauer L, Behm F, Cramblett M, Calkins K, Lawhon D . Psychopharmacological interactions between nicotine and ethanol. Nicotine Tob Res. 2004; 6(1):133-44. DOI: 10.1080/14622200310001656957. View

10.

Dani J, De Biasi M . Cellular mechanisms of nicotine addiction. Pharmacol Biochem Behav. 2002; 70(4):439-46. DOI: 10.1016/s0091-3057(01)00652-9. View

11.

Skradski S, White H . Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia. 2000; 41(S1):45-7. DOI: 10.1111/j.1528-1157.2000.tb02171.x. View

12.

Rose J, Behm F, Ramsey C, Ritchie Jr J . Platelet monoamine oxidase, smoking cessation, and tobacco withdrawal symptoms. Nicotine Tob Res. 2001; 3(4):383-90. DOI: 10.1080/14622200110087277. View

13.

Johnson B . Topiramate-induced neuromodulation of cortico-mesolimbic dopamine function: a new vista for the treatment of comorbid alcohol and nicotine dependence?. Addict Behav. 2004; 29(7):1465-79. DOI: 10.1016/j.addbeh.2004.06.014. View

14.

Henningfield J, OKeeffe M, Griffiths R . Effects of mecamylamine on human cigarette smoking and subjective ratings. Psychopharmacology (Berl). 1986; 88(4):420-5. DOI: 10.1007/BF00178502. View

15.

Rose J, Behm F, Westman E, Bates J . Mecamylamine acutely increases human intravenous nicotine self-administration. Pharmacol Biochem Behav. 2003; 76(2):307-13. DOI: 10.1016/j.pbb.2003.08.011. View

16.

Paterson N, Froestl W, Markou A . Repeated administration of the GABAB receptor agonist CGP44532 decreased nicotine self-administration, and acute administration decreased cue-induced reinstatement of nicotine-seeking in rats. Neuropsychopharmacology. 2004; 30(1):119-28. DOI: 10.1038/sj.npp.1300524. View

17.

Gonzalez S, Cascio M, Fernandez-Ruiz J, Fezza F, Di Marzo V, Ramos J . Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res. 2002; 954(1):73-81. DOI: 10.1016/s0006-8993(02)03344-9. View

18.

Caskey N, Jarvik M, Wirshing W, Madsen D, Eisenberger N, Huerta L . Modulating tobacco smoking rates by dopaminergic stimulation and blockade. Nicotine Tob Res. 2002; 4(3):259-66. DOI: 10.1080/14622200210153830. View

19.

Barrett J, DiSanto A, Thomford P, Larsen E, Palazzolo M, Morales R . Toxicokinetic evaluation of a selegiline transdermal system in the dog. Biopharm Drug Dispos. 1997; 18(2):165-84. DOI: 10.1002/(sici)1099-081x(199703)18:2<165::aid-bdd14>3.0.co;2-s. View

20.

Mahmood I . Clinical pharmacokinetics and pharmacodynamics of selegiline. An update. Clin Pharmacokinet. 1997; 33(2):91-102. DOI: 10.2165/00003088-199733020-00002. View